Moderna announces positive phase 3 efficacy data for mrna-1283, the company's next generation covid-19 vaccine

Mrna-1283 met its primary vaccine efficacy endpoint in a phase 3 trial, demonstrating non-inferior vaccine efficacy against covid-19 compared to spikevax® in participants 12 years of age and older higher efficacy was observed in mrna-1283 compared to spikevax in adults 18 years of age and older cambridge, ma / accesswire / june 13, 2024 / moderna, inc. (nasdaq:mrna) today announced that its phase 3 trial of mrna-1283, an investigational next-generation covid-19 vaccine, has met its primary efficacy endpoint, demonstrating non-inferior vaccine efficacy against covid-19 compared to spikevax. the company also announced that higher efficacy was observed in adults 18 years of age and older compared to spikevax (mrna-1273), with a consistent trend observed in the subset of adults age 65 and older.
MRNA Ratings Summary
MRNA Quant Ranking